Artemisinin triggers a G1 cell cycle arrest of human Ishikawa endometrial cancer cells and inhibits cyclin-dependent kinase-4 promoter activity and expression by disrupting nuclear factor-κB transcriptional signaling

Anti-Cancer Drugs

Volumn 25, Issue 3, 2014, Pages 270-281

  Tran, Kalvin Q ^a   Tin, Antony S ^a   Firestone, Gary L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Artemisinin antiproliferative signaling; CDK4 gene expression; Endometrial cancer cells; Nuclear factor B

Indexed keywords

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARTEMISIA ANNUA; ARTEMISININS; BASE SEQUENCE; CYCLIN-DEPENDENT KINASE 4; ENDOMETRIAL NEOPLASMS; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MOLECULAR SEQUENCE DATA; NF-KAPPA B; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84895075884     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000054     Document Type: Article

References (58)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Ryan AJ, Susil B, Jobling TW, Oehler MK. Endometrial cancer. Cell Tissue Res 2005; 322: 53-61.
3. Doll A, Abal M, Rigau M, Monge M, Gonzalez M, Demajo S, et al. Novel molecular profiles of endometrial cancer: new light through old windows. J Steroid Biochem Mol Biol 2008; 108: 221-229.
4. Felix AS, Weissfeld JL, Stone RA, Bowser R, Chivukula M, Edwards RP, et al. Factors associated with type I and type II endometrial cancer. Cancer Causes Control 2010; 21: 1851-1856.
5. Gagnon V, Van Themsche C, Turner S, Leblanc V, Asselin E. Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis 2008; 13: 259-271.
6. Chen S, Oh SR, Phung S, Hur G, Ye JJ, Kwok SL, et al. Anti-aromatase activity of phytochemicals in white button mushrooms (Agaricus bisporus). Cancer Res 2006; 66: 12026-12034.
7. Liu RH. Health benefits of fruit and vegetables are from additive and synergistic combinations of phytochemicals. Am J Clin Nutr 2003; 78:517S-520S.
8. Nonn L, Duong D, Peehl DM. Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells. Carcinogenesis 2007; 28: 1188-1196.
9. Neto CC. Cranberry and its phytochemicals: a review of in vitro anticancer studies. J Nutr 2007; 137:186S-193S.
10. Jeune MA, Kumi-Diaka J, Brown J. Anticancer activities of pomegranate extracts and genistein in human breast cancer cells. J Med Food 2005; 8: 469-475.
11. Wedge DE, Meepagala KM, Magee JB, Smith SH, Huang G, Larcom LL. Anticarcinogenic activity of strawberry, blueberry, and raspberry extracts to breast and cervical cancer cells. J Med Food 2001; 4: 49-51.
12. He X, Liu RH. Triterpenoids isolated from apple peels have potent antiproliferative activity and may be partially responsible for apple's anticancer activity. J Agric Food Chem 2007; 55: 4366-4370.
13. Firestone GL, Bjeldanes LF. Indole-3-carbinol and 3-30-diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter - Sp1 transcription factor interactions. J Nutr 2003; 133:2448S-2455S.
14. Leong H, Firestone GL, Bjeldanes LF. Cytostatic effects of 3, 30- diindolylmethane in human endometrial cancer cells result from an estrogen receptor-mediated increase in transforming growth factor-alpha expression. Carcinogenesis 2001; 22: 1809-1817.
15. Jayaprakasam B, Seeram NP, Nair MG. Anticancer and antiinflammatory activities of cucurbitacins from Cucurbita andreana. Cancer Lett 2003; 189: 11-16.
16. Kappagoda S, Singh U, Blackburn BG. Antiparasitic therapy. Mayo Clin Proc 2011; 86: 561-583.
17. Brasseur P, Badiane M, Cisse M, Agnamey P, Vaillant MT, Olliaro PL. Changing patterns of malaria during 1996-2010 in an area of moderate transmission in southern Senegal. Malar J 2011; 10:203.
18. Scott EN, Gescher AJ, Steward WP, Brown K. Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials. Cancer Prev Res (Phila) 2009; 2: 525-530.
19. Meshnick SR. Artemisinin and heme. Antimicrob Agents Chemother 2003; 47:2712 author reply 2712-2713.
20. Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol 2002; 32: 1655-1660.
21. Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The anti-malarial artesunate is also active against cancer. Int J Oncol 2001; 18: 767-773.
22. Tan W, Lu J, Huang M, Li Y, Chen M, Wu G, et al. Anti-cancer natural products isolated from Chinese medicinal herbs. Chin Med 2011; 6:27.
23. Cabello CM, Lamore SD, Bair WB III, Qiao S, Azimian S, Lesson JL, et al. The redox antimalarial dihydroartemisinin targets human metastatic melanoma cells but not primary melanocytes with induction of NOXA-dependent apoptosis. Invest New Drugs 2012; 30: 1289-1301.
24. Paik IH, Xie S, Shapiro TA, Labonte T, Narducci Sarjeant AA, Baege AC, et al. Second generation, orally active, antimalarial, artemisinin-derived trioxane dimers with high stability, efficacy, and anticancer activity. J Med Chem 2006; 49: 2731-2734.
25. Firestone GL, Sundar SN. Anticancer activities of artemisinin and its bioactive derivatives. Expert Rev Mol Med 2009; 11:e32.
26. Efferth T. Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr Drug Targets 2006; 7: 407-421.
27. Efferth T. Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin - from bench to bedside. Planta Med 2007; 73: 299-309.
28. Rosenthal PJ, Meshnick SR. Hemoglobin catabolism and iron utilization by malaria parasites. Mol Biochem Parasitol 1996; 83: 131-139.
29. Meshnick SR, Thomas A, Ranz A, Xu CM, Pan HZ. Artemisinin (qinghaosu): the role of intracellular hemin in its mechanism of antimalarial action. Mol Biochem Parasitol 1991; 49: 181-189.
30. Bustos MD, Gay F, Diquet B. In-vitro tests on Philippine isolates of Plasmodium falciparum against four standard antimalarials and four qinghaosu derivatives. Bull World Health Organ 1994; 72: 729-735.
31. Willoughby JA Sr, Sundar SN, Cheung M, Tin AS, Modiano J, Firestone GL. Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. J Biol Chem 2009; 284: 2203-2213.
32. Efferth T, Olbrich A, Bauer R. mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochem Pharmacol 2002; 64: 617-623.
33. Hou J, Wang D, Zhang R, Wang H. Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res 2008; 14: 5519-5530.
34. Tin AS, Sundar SN, Tran KQ, Park AH, Poindexter KM, Firestone GL. Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes. Anticancer Drugs 2012; 23: 370-379.
35. Marconett CN, Sundar SN, Poindexter KM, Stueve TR, Bjeldanes LF, Firestone GL. Indole-3-carbinol triggers aryl hydrocarbon receptor-dependent estrogen receptor (ER)alpha protein degradation in breast cancer cells disrupting an ERalpha-GATA3 transcriptional cross-regulatory loop. Mol Biol Cell 2010; 21: 1166-1177.
36. Sundar SN, Marconett CN, Doan VB, Willoughby JA Sr, Firestone GL. Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells. Carcinogenesis 2008; 29: 2252-2258.
37. Nguyen HH, Lavrenov SN, Sundar SN, Nguyen DH, Tseng M, Marconett CN, et al. 1-Benzyl-indole-3-carbinol is a novel indole-3-carbinol derivative with significantly enhanced potency of anti-proliferative and anti-estrogenic properties in human breast cancer cells. Chem Biol Interact 2010; 186: 255-266.
38. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004; 6: 203-208.
39. Mizumoto Y, Kyo S, Kiyono T, Takakura M, Nakamura M, Maida Y, et al. Activation of NF-kappaB is a novel target of KRAS-induced endometrial carcinogenesis. Clin Cancer Res 2011; 17: 1341-1350.
40. Darnell JE Jr. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002; 2: 740-749.
41. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-436.
42. Massague J. G1 cell-cycle control and cancer. Nature 2004; 432: 298-306.
43. Akl MR, Ayoub NM, Abuasal BS, Kaddoumi A, Sylvester PW. Sesamin synergistically potentiates the anticancer effects of gamma-tocotrienol in mammary cancer cell lines. Fitoterapia 2013; 84: 347-359.
44. Luo Q, Hu D, Hu S, Yan M, Sun Z, Chen F. In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma. BMC Cancer 2012; 12:517.
45. Rezaei PF, Fouladdel S, Ghaffari SM, Amin G, Azizi E. Induction of G1 cell cycle arrest and cyclin D1 down-regulation in response to pericarp extract of Baneh in human breast cancer T47D cells. Daru 2012; 20:101.
46. Marconett CN, Morgenstern TJ, San Roman AK, Sundar SN, Singhal AK, Firestone GL. BZL101, a phytochemical extract from the Scutellaria barbata plant, disrupts proliferation of human breast and prostate cancer cells through distinct mechanisms dependent on the cancer cell phenotype. Cancer Biol Ther 2010; 10: 397-405.
47. Aggarwal BB, Sung B. NF-kappaB in cancer: a matter of life and death. Cancer Discov 2011; 1: 469-471.
48. Aggarwal BB, Takada Y, Shishodia S, Gutierrez AM, Oommen OV, Ichikawa H, et al. Nuclear transcription factor NF-kappa B: role in biology and medicine. Indian J Exp Biol 2004; 42: 341-353.
49. Sorolla A, Yeramian A, Valls J, Dolcet X, Bergada L, Llombart-Cussac A, et al. Blockade of NFkappaB activity by sunitinib increases cell death in bortezomibtreated endometrial carcinoma cells. Mol Oncol 2012; 6: 530-541.
50. Saegusa M, Hashimura M, Kuwata T. Pin1 acts as a modulator of cell proliferation through alteration in NF-kappaB but not beta-catenin/TCF4 signalling in a subset of endometrial carcinoma cells. J Pathol 2010; 222: 410-420.
51. Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 2009; 1:a000034.
52. Razani B, Cheng G. NF-kappaB: much learned, much to learn. Sci Signal 2010; 3:pe29.
53. Wang Y, Huang Z, Wang L, Meng S, Fan Y, Chen T, et al. The anti-malarial artemisinin inhibits pro-inflammatory cytokines via the NF-kappaB canonical signaling pathway in PMA-induced THP-1 monocytes. Int J Mol Med 2011; 27: 233-241.
54. Zhu C, Xiong Z, Chen X, Peng F, Hu X, Chen Y, et al. Artemisinin attenuates lipopolysaccharide-stimulated proinflammatory responses by inhibiting NF-kappaB pathway in microglia cells. PLoS One 2012; 7:e35125.
55. Xiong Z, Sun G, Zhu C, Cheng B, Zhang C, Ma Y, et al. Artemisinin, an antimalarial agent, inhibits rat cardiac hypertrophy via inhibition of NF-kappaB signaling. Eur J Pharmacol 2010; 649: 277-284.
56. Wu X, Zhang W, Shi X, An P, Sun W, Wang Z. Therapeutic effect of artemisinin on lupus nephritis mice and its mechanisms. Acta Biochim Biophys Sin (Shanghai) 2010; 42: 916-923.
57. Chen H, Sun B, Wang S, Pan S, Gao Y, Bai X, et al. Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappaB. J Cancer Res Clin Oncol 2010; 136: 897-903.
58. Xu Q, Li ZX, Peng HQ, Sun ZW, Cheng RL, Ye ZM, et al. Artesunate inhibits growth and induces apoptosis in human osteosarcoma HOS cell line in vitro and in vivo. J Zhejiang Univ Sci B 2011; 12: 247-255.